MarketResearch.biz delivers in-depth insights on the global antifungal drug market in its upcoming report titled, “Global Antifungal Drug Market Trends, Applications, Analysis, Growth, and Forecast: 2017 to 2026”. The global antifungal drug market is estimated to register a CAGR of XXX% in terms of value during forecast period 2018–2027. The report offers in-depth insights, revenue details, and other vital information regarding the target market, and the various trends, drivers, restraints, opportunities, and threats till 2027. The report offers insightful and detailed information regarding the various key players operating in the market, their financials, supply chain trends, technological innovations, key developments, apart from future strategies, acquisitions & mergers, and market footprint. The global antifungal drug market report has been segmented on the basis of drug type, route of administration form, therapeutic indications, and region.
This report is based on synthesis, analysis, and interpretation of information gathered regarding the target market from various sources. Our analysts have analysed the information and data and gained insights using a mix of primary and secondary research efforts with the primary objective to provide a holistic view of the market. In addition, an in-house study has been made of the global economic conditions and other economic indicators and factors to assess their respective impact on the market historically, as well as the current impact in order to make informed forecasts about the scenarios in future.
Fungal infections are caused by microscopic organisms that can invade in the epithelial tissue. The fungal kingdom includes yeasts, molds, rusts and mushrooms. Fungi, like animals, are hetrotrophic, that is, they obtain nutrients from the environment. Most fungi are beneficial and are involved in biodegradation process. However, a few can cause fungal infections, if they are introduced into the skin through wounds, or into the lungs and nasal passages if inhaled etc. Diseases caused by fungi include superficial infections of the skin by dermatophytes in the microsporum, trichophyton or epidermophyton genera. Antifungals drugs mostly target specific components of fungal plasma membrane or its biosynthetic pathway for treatment.
Key factor expected to drive growth of the global antifungal drug market is increasing incidence of fungal disease. In addition, rising geriatric population, increasing awareness among population are the factors boosting the demand for global antifungal drug market. However, stringent laws by drug regulatory authority such as FDA, EMA may restraint the growth of the global antifungal drug market in the near future.
Key market players are focusing on new product launches, collaborations & mergers, and acquisitions to expand their global presence. Established players in the global antifungal drug market are directing towards formation of strong network of retailers & distributors, in order to expand their market. Government are taking initiatives for conducting various R&D activities of antifungal drugs
The market in North America is expected to dominate the global antifungal drug market, owing to increased incidence of fungal diseases. According to Center of Disease Control and Prevention (CDC), in 2017 approximately 46,000 new cases of invasive candidiasis occur every year in U.S. which is a common bloodstream infection in U.S. In contrast, Asia Pacific is expected to register highest CAGR for antifungal drug, owing to rising awareness toward personal care, rise in per capita income in this region.
GLOBAL ANTIFUNGAL DRUG MARKET SEGMENTATION:
Segmentation by drug type
- Others (Including econazole etc.)
- Amphotericin B
- Others (including Filipin, Hamycin etc.)
- Others (including terbinafine, amorolfin etc.)
- Others (Including tolnaftate, griseofulvin etc.)
Segmentation by route of administration:
Segmentation by route of therapeutic indication:
- Others (including blastomycosis, mucormycosis etc.)
Segmentation by region:
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Particular Scope Region
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East and Africa
- South Africa
- Rest of Middle East and Africa
Actual Year 2017 Estimated Year 2018 Forecast Period 2018–2027 Revenue in US$
- Pfizer Inc.
- Sanofi S.A
- Gilead Sciences, Inc.
- Merck & Co., Inc.
- Novartis International AG
- Abbott Laboratories
- Bayer AG
- Scynexis Inc.
- Enzon Pharmaceuticals, Inc.
- GlaxoSmithKline Plc.
Request for TOC
Request for Customization
Don't just take our word. We are trusted by these great companies!